https://scholars.lib.ntu.edu.tw/handle/123456789/457141
標題: | Raloxifene versus continuous combined estrogen/progestin therapy: Densitometric and biochemical effects in healthy postmenopausal Taiwanese women | 作者: | KEH-SUNG TSAI MEN-LUH YEN Pan H.A. Wu M.H. WERN-CHERNG CHENG SANDY HUEY-JEN HSU Yen B.L. Huang K.E. |
公開日期: | 2001 | 卷: | 12 | 期: | 12 | 起(迄)頁: | 1020-1025 | 來源出版物: | Osteoporosis International | 摘要: | We treated 116 healthy postmenopausal women (age 47-66 years, mean 57 years) in Taiwan with either raloxifene (RLX) 60 mg (n = 92) or 0.625 mg conjugated equine estrogen plus 5 mg medroxyprogesterone acetate (CCEP, n = 24) daily for 12 months in a randomized, double-masked, active-controlled fashion. The results showed that both regimens increased bone mineral density (BMD) at hip bip sites (means: RLX 2.5-4.9%, CCEP 4.6-7.9%, all p < 0.005 compared with baseline), and the difference between the two regimens was not significant. The spinal BMD increased significantly in both groups (1.4% with RLX and 6.0% with CCEP, both p < 0.01), and more with CCEP (p < 0.003). Osteocalcin levels and urinary type I collagen C-telopeptide/creatinine ratios decreased significantly in both regimens, but the decreases were significantly larger with CCEP. Compared with baseline, both RLX and CCEP decreased the total cholesterol (median 4.9% and 8.6% respectively, p < 0.001) and LDL-cholesterol (median 11% and 19% respectively, p < 0.001), and increased HDL-cholesterol (median 8.6% and 10.7% respectively, p < 0.01). Both regimens increased triglyceride levels (median 3.2% and 18.9% respectively, both p < 0.05), although to a lesser extent with RLX than with CCEP (p < 0.05). Only 3 subjects (3.3%) reported vaginal bleeding in the RLX group, as compared with 31% (7/22) with CCEP (p < 0.05). We conclude that in healthy, postmenopausal Taiwanese women, RLX 60 mg given daily has favorable results in BMD, bone turnover and serum lipids, although the dosage we used showed a potency less than that of conventional CCEP. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/457141 | ISSN: | 0937-941X | DOI: | 10.1007/s001980170011 | SDG/關鍵字: | collagen type 1; conjugated estrogen; conjugated estrogen plus medroxyprogesterone acetate; estrogen; gestagen; high density lipoprotein cholesterol; low density lipoprotein cholesterol; medroxyprogesterone acetate; osteocalcin; raloxifene; triacylglycerol; adult; aged; article; bone density; bone turnover; clinical trial; controlled clinical trial; controlled study; densitometry; double blind procedure; drug effect; drug potency; female; hip; human; lipid blood level; major clinical study; postmenopause osteoporosis; priority journal; randomized controlled trial; spine; vagina bleeding; Aged; Bone Density; Double-Blind Method; Drug Combinations; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hip Joint; Humans; Lipids; Lumbar Vertebrae; Medroxyprogesterone 17-Acetate; Middle Aged; Postmenopause; Progesterone Congeners; Raloxifene; Selective Estrogen Receptor Modulators; Uterus |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。